Guest: Naveen Pereira, MD
Host: Kyle Klarich, MD
Overview:
Genetic testing for coronary heart failure is most helpful for sufferers with cardiomyopathies. It aids in personalised therapy, early analysis, and household threat evaluation, though its uptake has been sluggish because of prices, entry, and interpretation challenges. Ongoing analysis into genetic mutations and their position in cardiomyopathy pathophysiology might result in new therapeutic targets and improved illness administration.
Questions:
1. Which sufferers with coronary heart failure ought to get genetic testing?
2. Why ought to genetic testing be carried out?
3. How is genetic testing carried out?
4. Why has there been a sluggish uptake in genetic testing for sufferers with cardiomyopathy? And what are some attainable options?
5. Can genetics present new perception into the pathophysiology of illness, particularly cardiomyopathies?
6. Can this data then be used to assist developed new therapeutic targets?
7. What are a number of the uncertainties within the subject that analysis must be centered on?
